Joseph P. Rybak

Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada.

Part of Incyte Corp., Maxia Pharmaceuticals, Inc. develops pharmaceutical products based on molecule drug discovery techniques. The company is based in San Diego, CA. The company was founded by David Perryman, Xian Ping Lu. Maxia Pharmaceuticals was acquired by Incyte Corp. on February 19, 2003 for $42.30 million.

Healthios Capital Markets LLC provides financial advisory services. The private company is based in Northbrook, IL and has subsidiaries in Thailand and Singapore. The company was founded by Fritz Reichenbach.

TheraFuse, Inc. designs and develops non-contact optical flow sensors for use in the commercial, industrial and medical applications. It offers delivery systems for insulin, pain medication, and protein drugs, disposable insulin patches for diabetics; and sprinkler hypodermic needles for sub-Q fluid delivery in drug pens. The company was founded in 2001 and is headquartered in Carlsbad, CA.

NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL.

SynVivo, Inc. is an American company that specializes in microfluidic organ-on-chip technology. The private company's platform allows for the real-time study of cellular behavior, drug delivery, and drug discovery.

Part of Telix Pharmaceuticals Ltd., IsoTherapeutics Group LLC is a radiopharmaceutical company that offers technologies for developing novel therapeutic and diagnostic agents. The company is based in Angleton, TX. The company was founded in 2005 by Jaime Simon, Keith R. Frank. Keith R. Frank has been the CEO of the company since 2005. IsoTherapeutics Group was acquired by Telix Pharmaceuticals Ltd. on April 09, 2024 for $13.63 million.